ALPMY Overview

Safety Profile Overview: The document outlines the safety profile for the Perioperative Enfortumab Vedotin, emphasizing its consistency with prior experiences involving the combination treatment.

Clinical Observations: Observations from clinical trials, specifically in the context of the EV-304 study, indicate that the safety profile aligns with previous findings, suggesting reliability in its application.

Strategic Collaborations: EvinoVA has announced strategic collaborations with major pharmaceutical companies including Astellas, AstraZeneca, and Bristol Myers Squibb.

Focus on Clinical Development: These partnerships aim to advance EvinoVA's AI-native platform to accelerate global clinical development efforts.

Positive Clinical Trial Results: Astellas Pharma and Pfizer reported successful topline results from the Phase 3 EV-304 trial, showing that the combination of PADCEV and Keytruda significantly improves event-free survival and overall survival in muscle-invasive bladder cancer patients compared to standard chemotherapy.

First Platinum-Free Regimen: The combination of PADCEV and Keytruda is the first platinum-free treatment to demonstrate improvements in both event-free and overall survival for cisplatin-eligible patients undergoing surgery for bladder cancer.

Improved Pathologic Response Rates: The trial also showed a significant increase in pathologic complete response rates for patients treated with PADCEV plus Keytruda compared to those receiving standard neoadjuvant chemotherapy.

Future Regulatory Steps: Findings from the EV-304 trial will be presented at a medical meeting and discussed with global health authorities to support potential regulatory filings for this new treatment approach.

Trial Results: Merck & Co. announced positive topline results from the Phase 3 KEYNOTE-B15 trial, showing that Keytruda combined with Padcev significantly improved event-free survival, overall survival, and pathologic complete response rates in muscle-invasive bladder cancer patients eligible for cisplatin-based chemotherapy.

Safety Profile: The safety profile of the Keytruda and Padcev combination was consistent with known safety profiles, with no new safety signals identified during the trial.

Future Plans: Merck and its partners plan to present the trial results to regulatory authorities for potential filings and will share the data at an upcoming medical meeting.

Ongoing Research: Three additional Phase 3 studies are underway to evaluate Keytruda across various stages of bladder cancer, including two focused on muscle-invasive bladder cancer.

Clinical Study Results: Monte Rosa Therapeutics shared interim data from a Phase 1/2 study of MRT-2359 combined with enzalutamide in patients with metastatic castration-resistant prostate cancer, showing a favorable safety profile and promising disease control rates, particularly in patients with AR mutations.

Future Plans: The company plans to present updated data at the ASCO Genitourinary Cancers Symposium in February and initiate a Phase 2 study in 2026 to further assess the efficacy of MRT-2359 in combination with a second-generation AR inhibitor.

Additional Findings: The Phase 1/2 study also included patients with hormone receptor-positive breast cancer, but results did not support further development in this population despite a favorable safety profile.

Stock Performance: Following the announcement, Monte Rosa's stock (GLUE) rose by 11.43%, reaching $18.33.

EMA Review Validation: Astellas Pharma's application for a Type II variation for PADCEV (enfortumab vedotin) has been validated by the European Medicines Agency, seeking approval for its use in combination with KEYTRUDA (pembrolizumab) for treating muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy.

Neoadjuvant and Adjuvant Therapy: The application proposes using the combination therapy as neoadjuvant treatment before radical cystectomy and continuing it as adjuvant therapy post-surgery, aiming to provide more treatment options for MIBC patients.

Clinical Trial Results: The Type II variation application is supported by Phase 3 EV-303 clinical trial results, which demonstrated a 60% reduction in the risk of tumor recurrence, progression, or death, and a 50% reduction in the risk of death, with consistent safety results.

Future Steps: The EMA's Committee for Medicinal Products for Human Use and the European Commission are expected to provide their opinions and decisions on the application by the calendar year 2026.